文献速递冠心病

血小板FcγRIIa作为心肌梗死后心血管风险标志物

Platelet FcγRIIa as a Marker of Cardiovascular Risk After Myocardial Infarction.
PubMed 文献 · J Am Coll Cardiol · 2024-01-01

多中心前瞻性研究纳入800例1型心肌梗死患者,用流式细胞术检测血小板FcγRIIa(pFCG)水平。高pFCG组主要复合终点(心梗、卒中、死亡)发生率更高(HR: 2.09; 95% CI: 1.34-3.26; P = 0.001),死亡和心梗单独分析亦更高。pFCG可区分后续心血管事件风险高低,有助于指导抗血小板治疗强度和疗程。

要点

  • 高pFCG组主要复合终点风险是低pFCG组的2.09倍(95% CI: 1.34-3.26)。
  • 高pFCG组死亡风险HR: 2.57(95% CI: 1.50-4.40),心梗风险HR: 3.24(95% CI: 1.64-6.37)。
  • 两组抗栓治疗(阿司匹林、P2Y12抑制剂、抗凝药)使用情况相似。

核心结论

  • 定量检测pFCG可识别心肌梗死后后续心血管事件风险较高和较低的患者。
  • 该预后信息有助于临床决策抗血小板治疗的强度和疗程。

研究设计与样本

  • 前瞻性非干预性多中心研究,纳入800例1型心肌梗死(ST段抬高和非ST段抬高)患者,覆盖25个中心。
  • 入组患者需至少具备以下2项特征:年龄≥65岁、多支冠状动脉病变、既往心梗、慢性肾脏病或糖尿病。
  • 核心实验室用流式细胞术定量pFCG,采用预设阈值区分高、低pFCG。
  • 每6个月电话标准化问卷随访,事件经病历复核确认。

主要发现

  • 高pFCG组主要复合终点(心梗、卒中、死亡)发生率更高(HR: 2.09; 95% CI: 1.34-3.26; P = 0.001)。
  • 高pFCG组死亡发生率更高(HR: 2.57; 95% CI: 1.50-4.40; P = 0.001)。
  • 高pFCG组心梗发生率更高(HR: 3.24; 95% CI: 1.64-6.37; P = 0.001)。
  • 高pFCG与低pFCG组抗栓治疗(阿司匹林、P2Y12抑制剂、抗凝药)使用情况相似。

临床怎么用

  • 对心肌梗死后患者可考虑检测pFCG以辅助风险分层。
  • 高pFCG患者可能需加强或延长抗血小板治疗,但需结合临床综合判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A previous single-center study of patients with myocardial infarction (MI) showed that platelet FcγRIIa (pFCG) can distinguish patients at higher and lower risk of subsequent MI, stroke, and death. OBJECTIVES: The authors performed an 800-patient 25-center study to validate the prognostic implications of pFCG. METHODS: Patients with type 1 MI (ST-segment elevation and non-ST-segment elevation) were enrolled in a prospective noninterventional trial during their index hospitalization. Enrolled patients had at least 2 of the following characteristics: age ≥65 years, multivessel coronary artery disease, previous MI, chronic kidney disease, or diabetes mellitus. Flow cytometry was used to quantify pFCG at a core laboratory. A predefined threshold was used to identify high and low pFCG. Patients were queried every 6 months by telephone with a standardized questionnaire. Events were confirmed by review of medical records. RESULTS: Treatment with antithrombotic therapy (aspirin, P2Y12 inhibitors, and anticoagulants) was similar in patients with high and low pFCG. The primary composite endpoint (MI, stroke, death) occurred more frequently in patients with high pFCG (HR: 2.09; 95% CI: 1.34-3.26; P = 0.001). Among individual components of the composite, both death (HR: 2.57; 95% CI: 1.50-4.40; P = 0.001) and MI (HR: 3.24; 95% CI: 1.64-6.37; P = 0.001) were more frequent in patients with high pFCG. CONCLUSIONS: Quantifying pFCG identifies patients at higher and lower risk of subsequent cardiovascular events. This prognostic information will be useful in clinical decisions regarding the intensity and duration of antiplatelet therapy. (Assessment of Individual Risk of Cardiovascular Events by Platelet FcγRIIa; NCT05175261).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Schneider, McMahon, Angiolillo, et al. Platelet FcγRIIa as a Marker of Cardiovascular Risk After Myocardial Infarction. J Am Coll Cardiol. 2024. PMID: 39443015. doi:10.1016/j.jacc.2024.08.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。